company background image
BSX

Boston Scientific NYSE:BSX Stock Report

Last Price

US$40.94

Market Cap

US$58.6b

7D

-0.3%

1Y

-8.4%

Updated

06 Aug, 2022

Data

Company Financials +
BSX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance4/6
Financial Health3/6
Dividends0/6

BSX Stock Overview

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.

Boston Scientific Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Boston Scientific
Historical stock prices
Current Share PriceUS$40.94
52 Week HighUS$47.50
52 Week LowUS$34.98
Beta0.85
1 Month Change8.16%
3 Month Change0.22%
1 Year Change-8.41%
3 Year Change-5.23%
5 Year Change55.02%
Change since IPO856.26%

Recent News & Updates

Jul 27
Boston Scientific Corporation (NYSE:BSX) Shares Could Be 23% Below Their Intrinsic Value Estimate

Boston Scientific Corporation (NYSE:BSX) Shares Could Be 23% Below Their Intrinsic Value Estimate

Does the July share price for Boston Scientific Corporation ( NYSE:BSX ) reflect what it's really worth? Today, we will...

Shareholder Returns

BSXUS Medical EquipmentUS Market
7D-0.3%2.4%1.0%
1Y-8.4%-21.6%-12.9%

Return vs Industry: BSX exceeded the US Medical Equipment industry which returned -21.6% over the past year.

Return vs Market: BSX exceeded the US Market which returned -12.8% over the past year.

Price Volatility

Is BSX's price volatile compared to industry and market?
BSX volatility
BSX Average Weekly Movement3.9%
Medical Equipment Industry Average Movement9.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: BSX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: BSX's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
197941,000Mike Mahoneyhttps://www.bostonscientific.com

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

Boston Scientific Fundamentals Summary

How do Boston Scientific's earnings and revenue compare to its market cap?
BSX fundamental statistics
Market CapUS$58.61b
Earnings (TTM)US$829.00m
Revenue (TTM)US$12.33b

70.7x

P/E Ratio

4.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BSX income statement (TTM)
RevenueUS$12.33b
Cost of RevenueUS$3.77b
Gross ProfitUS$8.56b
Other ExpensesUS$7.73b
EarningsUS$829.00m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.58
Gross Margin69.40%
Net Profit Margin6.72%
Debt/Equity Ratio52.0%

How did BSX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BSX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BSX?

Other financial metrics that can be useful for relative valuation.

BSX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.5x
Enterprise Value/EBITDA20.9x
PEG Ratio2.9x

Price to Earnings Ratio vs Peers

How does BSX's PE Ratio compare to its peers?

BSX PE Ratio vs Peers
The above table shows the PE ratio for BSX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average45.6x
EW Edwards Lifesciences
45.2x11.1%US$65.8b
BDX Becton Dickinson
38.2x11.6%US$72.5b
SYK Stryker
39.3x14.4%US$81.6b
ISRG Intuitive Surgical
59.8x17.2%US$85.8b
BSX Boston Scientific
70.7x24.8%US$58.6b

Price-To-Earnings vs Peers: BSX is expensive based on its Price-To-Earnings Ratio (70.7x) compared to the peer average (45.6x).


Price to Earnings Ratio vs Industry

How does BSX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

Price-To-Earnings vs Industry: BSX is expensive based on its Price-To-Earnings Ratio (70.7x) compared to the US Medical Equipment industry average (33.9x)


Price to Earnings Ratio vs Fair Ratio

What is BSX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BSX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio70.7x
Fair PE Ratio49x

Price-To-Earnings vs Fair Ratio: BSX is expensive based on its Price-To-Earnings Ratio (70.7x) compared to the estimated Fair Price-To-Earnings Ratio (49x).


Share Price vs Fair Value

What is the Fair Price of BSX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BSX ($40.94) is trading below our estimate of fair value ($54.16)

Significantly Below Fair Value: BSX is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is Boston Scientific forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


24.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BSX's forecast earnings growth (24.8% per year) is above the savings rate (1.9%).

Earnings vs Market: BSX's earnings (24.8% per year) are forecast to grow faster than the US market (12.8% per year).

High Growth Earnings: BSX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BSX's revenue (7% per year) is forecast to grow slower than the US market (7.9% per year).

High Growth Revenue: BSX's revenue (7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BSX's Return on Equity is forecast to be low in 3 years time (15.2%).


Discover growth companies

Past Performance

How has Boston Scientific performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


6.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BSX has a large one-off loss of $475.0M impacting its June 30 2022 financial results.

Growing Profit Margin: BSX's current net profit margins (6.7%) are higher than last year (4.7%).


Past Earnings Growth Analysis

Earnings Trend: BSX's earnings have grown by 6.6% per year over the past 5 years.

Accelerating Growth: BSX's earnings growth over the past year (57.6%) exceeds its 5-year average (6.6% per year).

Earnings vs Industry: BSX earnings growth over the past year (57.6%) exceeded the Medical Equipment industry 2%.


Return on Equity

High ROE: BSX's Return on Equity (5.1%) is considered low.


Discover strong past performing companies

Financial Health

How is Boston Scientific's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: BSX's short term assets ($5.1B) exceed its short term liabilities ($3.9B).

Long Term Liabilities: BSX's short term assets ($5.1B) do not cover its long term liabilities ($11.1B).


Debt to Equity History and Analysis

Debt Level: BSX's net debt to equity ratio (50.4%) is considered high.

Reducing Debt: BSX's debt to equity ratio has reduced from 80.6% to 52% over the past 5 years.

Debt Coverage: BSX's debt is not well covered by operating cash flow (13.3%).

Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (4.2x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Boston Scientific current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BSX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BSX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BSX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BSX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.6yrs

Average management tenure


CEO

Mike Mahoney (57 yo)

10.83yrs

Tenure

US$16,064,039

Compensation

Mr. Michael F. Mahoney, also known as Mike, has been Chairman of Boston Scientific Corporation since May 3, 2016, and is its Chief Executive Officer since November 1, 2012 and has been its President since...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD16.06M) is about average for companies of similar size in the US market ($USD13.00M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BSX's management team is seasoned and experienced (8.6 years average tenure).


Board Members

Experienced Board: BSX's board of directors are considered experienced (7.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BSX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Boston Scientific Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Boston Scientific Corporation
  • Ticker: BSX
  • Exchange: NYSE
  • Founded: 1979
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$58.610b
  • Shares outstanding: 1.43b
  • Website: https://www.bostonscientific.com

Number of Employees


Location

  • Boston Scientific Corporation
  • 300 Boston Scientific Way
  • Marlborough
  • Massachusetts
  • 01752-1234
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/06 00:00
End of Day Share Price2022/08/05 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.